 |
18 Diseases |  |
32 Trials |
|
32 Trials |  |
839 News |  |
| «12...45678910111213141516» |
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open, Pneumococcal vaccines: Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines (clinicaltrials.gov) - May 6, 2017
P=N/A, N=40, Recruiting, Sponsor: The Jackson Laboratory
Not yet recruiting --> Recruiting
- | lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 25, 2017
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jul 2016
- | Entyvio (vedolizumab) / Takeda
Trial initiation date: Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab (clinicaltrials.gov) - Apr 19, 2017
P=N/A, N=400, Not yet recruiting, Sponsor: Boston Medical Center
Trial primary completion date: Dec 2016 --> Jul 2016 Initiation date: Mar 2017 --> Jun 2017
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New trial, Pneumococcal vaccines: Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=40, Not yet recruiting, Sponsor: The Jackson Laboratory
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial, Pneumococcal vaccines: Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia (clinicaltrials.gov) - Mar 29, 2017
P4, N=56, Completed, Sponsor: Fakultas Kedokteran Universitas Indonesia
- | Rituxan (rituximab) / Roche
New P2 trial, Pneumococcal vaccines: PNEUMOVAS: Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (clinicaltrials.gov) - Mar 3, 2017
P2, N=120, Not yet recruiting, Sponsor: Assistance Publique - H
- lenalidomide / Generic mfg.
Trial termination: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 24, 2017
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Initiation date: Mar 2017 --> Jun 2017 Active, not recruiting --> Terminated; Slow Accrual
- | Entyvio (vedolizumab) / Takeda
New trial: Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=400, Not yet recruiting, Sponsor: Boston Medical Center
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial primary completion date: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=90, Recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Terminated; Slow Accrual Trial primary completion date: Jun 2017 --> Apr 2018
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New trial, IO biomarker, Pneumococcal vaccines: Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=160, Recruiting, Sponsor: Medical University of South Carolina
- Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
Trial completion, Trial primary completion date: Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (clinicaltrials.gov) - Dec 27, 2016
P1/2, N=346, Completed, Sponsor: PATH
Trial primary completion date: Jun 2017 --> Apr 2018 Trial primary completion date: Oct 2016 --> Apr 2016 | Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Phase classification: Pneumococcal Reference Standard (clinicaltrials.gov) - Dec 27, 2016
P1, N=250, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2016 --> Apr 2016 | Active, not recruiting --> Completed Phase classification: P=N/A --> P1
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open, Trial initiation date: ROVE: Effect of Obesity on Immune Response to Pneumovax 23 (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=56, Recruiting, Sponsor: University of Florida
Phase classification: P=N/A --> P1 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial primary completion date: Systems Biology of PNEUMOVAX (clinicaltrials.gov) - Dec 12, 2016
P=N/A, N=88, Active, not recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016 Trial primary completion date: Nov 2016 --> Dec 2017
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Fluarix (influenza virus trivalent vaccine) / GSK
Enrollment open: Perturbing of HIV Reservoir With Immune Stimulation (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=56, Recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Nov 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- lenalidomide / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 11, 2016
P2, N=3, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=35 --> 3 | Trial primary completion date: Nov 2017 --> Nov 2018
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine (clinicaltrials.gov) - Oct 3, 2016
P4, N=162, Completed, Sponsor: Kameda Medical Center
Recruiting --> Active, not recruiting | N=35 --> 3 | Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial primary completion date: ROVE: Effect of Obesity on Immune Response to Pneumovax 23 (clinicaltrials.gov) - Sep 20, 2016
P=N/A, N=56, Not yet recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> May 2018
- Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
Enrollment closed, Trial primary completion date: Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=346, Active, not recruiting, Sponsor: PATH
Trial primary completion date: May 2017 --> May 2018 Completed --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2016
- |||| dimethyl fumarate / Generic mfg.
Trial completion: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Aug 24, 2016
P2, N=71, Completed, Sponsor: Biogen
Completed --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2016 Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open: Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma (clinicaltrials.gov) - Aug 24, 2016
P1, N=260, Recruiting, Sponsor: Rohit Divekar
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial initiation date: ROVE: Effect of Obesity on Immune Response to Pneumovax 23 (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=56, Not yet recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Initiation date: Jun 2016 --> Sep 2016
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial initiation date, Trial primary completion date, IO biomarker, Pneumococcal vaccines: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (clinicaltrials.gov) - Aug 9, 2016
P4, N=132, Not yet recruiting, Sponsor: Jena University Hospital
Initiation date: Jun 2016 --> Sep 2016 Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2019 --> Jan 2020
- ||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Trial completion: Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23 (clinicaltrials.gov) - Jul 29, 2016
P3, N=865, Completed, Sponsor: GlaxoSmithKline
Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2019 --> Jan 2020 Active, not recruiting --> Completed
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P2 trial, Surgery: Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery (clinicaltrials.gov) - Jun 20, 2016
P2, N=85, Completed, Sponsor: Uppsala University
- Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
Trial completion: Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (clinicaltrials.gov) - Jun 18, 2016
P1/2, N=346, Completed, Sponsor: PATH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change, Trial initiation date, Trial primary completion date, IO biomarker, Pneumococcal vaccines: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (clinicaltrials.gov) - Jun 9, 2016
P4, N=132, Not yet recruiting, Sponsor: Jena University Hospital
Active, not recruiting --> Completed N=74 --> 132 | Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Dec 2017 --> Jul 2019
- | lenalidomide / Generic mfg.
Enrollment open: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 12, 2016
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=74 --> 132 | Initiation date: Jan 2016 --> Jul 2016 | Trial primary completion date: Dec 2017 --> Jul 2019 Active, not recruiting --> Recruiting
- ||| dimethyl fumarate / Generic mfg.
Enrollment closed: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - May 11, 2016
P2, N=71, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 6, 2016
P2, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
Trial primary completion date: Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (clinicaltrials.gov) - Apr 9, 2016
P1/2, N=346, Active, not recruiting, Sponsor: PATH
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> May 2016
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P1 trial: Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma (clinicaltrials.gov) - Mar 25, 2016
P1, N=260, Not yet recruiting, Sponsor: Rohit Divekar
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment closed: SOT13: Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients (clinicaltrials.gov) - Mar 21, 2016
P4, N=182, Active, not recruiting, Sponsor: Helsinki University Central Hospital
Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Active, not recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Fluarix (influenza virus trivalent vaccine) / GSK
New trial: Perturbing of HIV Reservoir With Immune Stimulation (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=56, Not yet recruiting, Sponsor: University of California, San Diego
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial primary completion date: Systems Biology of PNEUMOVAX (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=88, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Nov 2016
- ||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) (clinicaltrials.gov) - Feb 27, 2016
P3, N=130, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2016 --> Nov 2016 Terminated --> Completed
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial completion: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13 (clinicaltrials.gov) - Feb 9, 2016
P2, N=253, Completed, Sponsor: Merck Sharp & Dohme Corp.
Terminated --> Completed Active, not recruiting --> Completed
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment closed, Pneumococcal vaccines: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine (clinicaltrials.gov) - Feb 5, 2016
P4, N=162, Active, not recruiting, Sponsor: Kameda Medical Center
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Trial primary completion date, Pneumococcal vaccines: Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - Jan 27, 2016
P3, N=767, Completed, Sponsor: SK Chemicals Co.,Ltd.
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Completed | Trial primary completion date: Apr 2014 --> Oct 2014
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment closed: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13 (clinicaltrials.gov) - Jan 22, 2016
P2, N=250, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Completed | Trial primary completion date: Apr 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open, Trial initiation date, Trial primary completion date: Vaccinating Children After Chemotherapy (clinicaltrials.gov) - Jan 21, 2016
P4, N=200, Recruiting, Sponsor: Dalhousie University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Jul 2017 --> Dec 2017
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Trial primary completion date, Pneumococcal vaccines: Pneumococcal Vaccine in Untreated CLL Patients (clinicaltrials.gov) - Jan 15, 2016
P3, N=134, Completed, Sponsor: Karolinska University Hospital
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Jul 2017 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2015
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Phase classification, Pneumococcal vaccines: Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine (clinicaltrials.gov) - Jan 12, 2016
P1, N=100, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2015 Phase classification: P=N/A --> P1
- ||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Trial completion, Enrollment change: A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants (clinicaltrials.gov) - Jan 11, 2016
P1, N=84, Completed, Sponsor: Eli Lilly and Company
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | N=60 --> 84
- Pneumosil (10-valent pneumococcal conjugate vaccine) / Serum Institute of India
Enrollment closed: Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants (clinicaltrials.gov) - Jan 6, 2016
P1/2, N=346, Active, not recruiting, Sponsor: PATH
Active, not recruiting --> Completed | N=60 --> 84 Recruiting --> Active, not recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial, IO biomarker, Pneumococcal vaccines: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (clinicaltrials.gov) - Dec 22, 2015
P4, N=74, Not yet recruiting, Sponsor: Jena University Hospital
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial primary completion date: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=90, Recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- || dimethyl fumarate / Generic mfg.
Trial primary completion date: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Dec 5, 2015
P2, N=70, Recruiting, Sponsor: Biogen
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Nov 2015 --> Jul 2016
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment change, Trial termination, IO biomarker, Surgery: Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 30, 2015
P=N/A, N=16, Terminated, Sponsor: Mayo Clinic
Trial primary completion date: Nov 2015 --> Jul 2016 N=26 --> 16 | Suspended --> Terminated
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment status, Pneumococcal vaccines: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine (clinicaltrials.gov) - Nov 28, 2015
P4, N=162, Enrolling by invitation, Sponsor: Kameda Medical Center
N=26 --> 16 | Suspended --> Terminated Recruiting --> Enrolling by invitation